Matthew T. Roe, MD
and David J. Moliterno, MD
- Cleveland Clinic Journal of Medicine May 1998, 65 (5) 267-272;
The platelet glycoprotein Ilb/IIIa inhibitor abciximab, together with heparin in a low, weight-adjusted dose, markedly reduced the risk of acute ischemic complications during angioplasty, without increasing the risk of hemorrhage.
